WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming conferences in September 2017.
- Baird 2017 Global Healthcare Conference – New York, NY (September 6-7, 2017)
Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview on Thursday, September 7 at 10:15 AM EDT. The conference will be held at the InterContinental New York Barclay in New York City. The presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be archived and available on Histogenics’ website for 45 days following the conferences.
- 19th Annual Rodman & Renshaw Global Investment Conference – New York, NY (September 10-12, 2017)
Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview on Monday, September 11 at 10:00 AM EDT. The conference is sponsored by H.C. Wainwright & Co., LLC., and will be held at the Lotte New York Palace Hotel in New York City. The presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be archived and available on Histogenics’ website for 45 days following the conferences.
- Healthcare Capital & Connections Summit – Shanghai, China (September 12-14, 2017)
Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting a corporate overview on Wednesday, September 13 at 2:00 PM local time. The conference is sponsored by Silicon Valley Bank, AdvaMed Accel, Piper Jaffray and Vivo Capital and will be held at the InterContinental Ruijin in Shanghai.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo. Histogenics’ first investigational product candidate, NeoCart is designed to treat cartilage defects in the knee. The Company recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line data in the third quarter of 2018. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage. As a result, NeoCart is the only product in development or on the market with a one-year primary superiority endpoint as compared to the standard of care. There are more than 500,000 or more knee cartilage procedures in the United States each year, with many healthy active adults avoiding treatment as they seek other alternatives. Left untreated, even a small cartilage defect can expand in size and progress to debilitating osteoarthritis, ultimately necessitating a joint replacement procedure. Osteoarthritis is more common in adults over the age of 50, but the condition and precursors of the condition can be observed much earlier, and cartilage damage is believed to be one of the leading contributors of this disease. For more information, please visit www.histogenics.com.
CONTACT: Contact: Investor Relations Tel: +1 (781) 547-7909 InvestorRelations@histogenics.com